BSR_02_0049_A5_S69
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.690
- INTERFERON_GAMMA_RESPONSE+0.690
- INTERFERON_ALPHA_RESPONSE+0.670
- IL6_JAK_STAT3_SIGNALING+0.560
- COMPLEMENT+0.510
- INFLAMMATORY_RESPONSE+0.510
- TNFA_SIGNALING_VIA_NFKB+0.340
- IL2_STAT5_SIGNALING+0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.330
- KRAS_SIGNALING_UP+0.290
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.490
- ESTROGEN_RESPONSE_LATE-0.440
- MYC_TARGETS_V2-0.430
- CHOLESTEROL_HOMEOSTASIS-0.410
- NOTCH_SIGNALING-0.380
- GLYCOLYSIS-0.300
- ADIPOGENESIS-0.240
- MYC_TARGETS_V1-0.240
- MYOGENESIS-0.240
- HEDGEHOG_SIGNALING-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613787 | — | D | 0.921 |
| 2 | ERR2208965 | — | — | 0.906 |
| 3 | SRR8518387 | — | D | 0.903 |
| 4 | SRR8518123 | — | D | 0.893 |
| 5 | SRR8518190 | — | D | 0.882 |
| 6 | SRR8518228 | — | D | 0.876 |
| 7 | SRR10842377 | — | — | 0.868 |
| 8 | TCGA-AR-A1AW-01A-21R-A12P-07 | — | D | 0.856 |
| 9 | SRR8518212 | — | D | 0.856 |
| 10 | ERR2208913 | — | — | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.690 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.690 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.670 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.560 | Inavolisib | — uncovered |
| COMPLEMENT | 0.510 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.510 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.330 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.230 | Inavolisib | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.030 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.010 | Inavolisib | — uncovered |